Cabtreo is a drug owned by Bausch Health Us Llc. It is protected by 5 US drug patents filed in 2023 out of which none have expired yet. Based on its patents and exclusivities, its generic launch date is estimated to be Dec 28, 2040. Details of Cabtreo's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US11389467 | Topical compositions |
Dec, 2040
(16 years from now) | Active |
| US8288434 | Topical pharmaceutical formulations containing a low concentration of benzoyl peroxide in suspension in water and a water-miscible organic solvent |
Aug, 2029
(4 years from now) | Active |
| US10624918 | Topical pharmaceutical formulations containing a low concentration of benzoyl peroxide in suspension in water and a water-miscible organic solvent |
Jun, 2029
(4 years from now) | Active |
| US10220049 | Topical pharmaceutical formulations containing a low concentration of benzoyl peroxide in suspension in water and a water-miscible organic solvent |
Jun, 2029
(4 years from now) | Active |
| US9561208 | Topical pharmaceutical formulations containing a low concentration of benzoyl peroxide in suspension in water and a water-miscible organic solvent |
Jun, 2029
(4 years from now) | Active |
A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Cabtreo's patents.
Latest Legal Activities on Cabtreo's Patents
Given below is the list of recent legal activities going on the following patents of Cabtreo.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 12th Year, Large Entity | 20 Mar, 2024 | US8288434 (Litigated) |
| Payment of Maintenance Fee, 4th Year, Large Entity | 20 Sep, 2023 | US10624918 |
| Post Issue Communication - Certificate of Correction | 14 Sep, 2022 | US11389467 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 18 Aug, 2022 | US10220049 |
| Patent Issue Date Used in PTA Calculation Critical | 19 Jul, 2022 | US11389467 |
| Recordation of Patent Grant Mailed Critical | 19 Jul, 2022 | US11389467 |
| Email Notification Critical | 30 Jun, 2022 | US11389467 |
| Issue Notification Mailed Critical | 29 Jun, 2022 | US11389467 |
| Application Is Considered Ready for Issue Critical | 20 Jun, 2022 | US11389467 |
| Dispatch to FDC | 20 Jun, 2022 | US11389467 |
FDA has granted several exclusivities to Cabtreo. Till the time these exclusivities are active, no other company can market a generic or bioequivalent version of Cabtreo, regardless of the status of it's patents. These exclusivities hence play a crucial role in delaying the generic launch. Given below are details of the exclusivities granted to Cabtreo.
Exclusivity Information
Cabtreo holds 1 exclusivities out of which none have expired. Its last outstanding exclusivity is set to expire in 2026. Details of Cabtreo's exclusivity codes and their expiration dates are given below.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Oct 20, 2026 |
US patents provide insights into the exclusivity only within the United States, but Cabtreo is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Cabtreo's family patents as well as insights into ongoing legal events on those patents.
Cabtreo's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Cabtreo's generic launch date based on the last expiry date of its patents and exclusivities combined is estimated to be Dec 28, 2040 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Cabtreo Generics:
There are no approved generic versions for Cabtreo as of now.
About Cabtreo
Cabtreo is a drug owned by Bausch Health Us Llc. It is used for treating acne vulgaris in patients 12 years of age and older. Cabtreo uses Adapalene; Benzoyl Peroxide; Clindamycin Phosphate as an active ingredient. Cabtreo was launched by Bausch in 2023.
Approval Date:
Cabtreo was approved by FDA for market use on 20 October, 2023.
Active Ingredient:
Cabtreo uses Adapalene; Benzoyl Peroxide; Clindamycin Phosphate as the active ingredient. Check out other Drugs and Companies using Adapalene; Benzoyl Peroxide; Clindamycin Phosphate ingredient
Treatment:
Cabtreo is used for treating acne vulgaris in patients 12 years of age and older.
Dosage:
Cabtreo is available in gel form for topical use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| 0.15%;3.1%;1.2% | GEL | Prescription | TOPICAL |